Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

FDA grants accelerated approval to tazemetostat for follicular lymphoma

FDA grants accelerated approval to tazemetostat for follicular lymphoma

$FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma$

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma

Early clinical trial supports tumour cell-based vaccine for mantle cell lymphoma

Early clinical trial supports tumour cell-based vaccine for mantle cell lymphoma

FDA approves gemtuzumab ozogamicin for CD33-positive AML in paediatric patients

FDA approves gemtuzumab ozogamicin for CD33-positive AML in paediatric patients

Researchers generate developmental map of human T-cells

Researchers generate developmental map of human T-cells

Cytokine implicated in HLH treatment resistance

Cytokine implicated in HLH treatment resistance

EHA 2020: Advances in treatment of high-risk chronic lymphocytic leukaemia

EHA 2020: Advances in treatment of high-risk chronic lymphocytic leukaemia

EHA 2020: Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice

EHA 2020: Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in...

EHA 2020: Promising treatment results with imetelstat, a novel telomerase inhibitor, in patients with lower risk myelodysplastic syndromes

EHA 2020: Promising treatment results with imetelstat, a novel telomerase inhibitor, in patients with lower risk...

$EHA 2020: A new treatment paradigm in relapsed refractory Hodgkin lymphoma$

EHA 2020: A new treatment paradigm in relapsed refractory Hodgkin lymphoma

More from ecancer